CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 82 enrolled
Drug / intervention
Laquinimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01085084
NCT01085084Phase 2Completed
CompareCT.gov

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis

Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Mar 11, 2010·Updated Jul 7, 2022

In Brief

A Phase 2 clinical trial evaluating Laquinimod and Placebo for Lupus Arthritis. Completed, enrolled 82 participants across 22 sites in 2 countries.

Detailed Summary

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams \[mg\] and 1 mg) in participants with active lupus arthritis. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Arthritis
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 11, 2010
Enrollment StartOct 4, 2010
Primary CompletionNov 12, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.3 years ago

Interventions

Laquinimoddrug

Laquinimod will be administered per dose and schedule specified in the arm description.

Placebodrug

Placebo matching to laquinimod will be administered per schedule specified in the arm description.